RT Journal Article
T1 Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies
A1 Ambrosini, Giulia
A1 Cordani, Marco
A1 Zarrabi, Ali
A1 Alcon-Rodriguez, Sergio
A1 Sainz, Rosa
A1 Velasco Díez, Guillermo
A1 González-Menéndez, Pedro
A1 Dando, Ilaria
AB Prostate cancer, as one of the most prevalent malignancies in males, exhibits an approximate 5-year survival rate of 95% in advanced stages. A myriad of molecular events and mutations, including the accumulation of oncometabolites, underpin the genesis and progression of this cancer type. Despite growing research demonstrating the pivotal role of oncometabolites in supporting various cancers, including prostate cancer, the root causes of their accumulation, especially in the absence of enzymatic mutations, remain elusive. Consequently, identifying a tangible therapeutic target poses a formidable challenge. In this review, we aim to delve deeper into the implications of oncometabolite accumulation in prostate cancer. We center our focus on the consequential epigenetic alterations and impacts on cancer stem cells, with the ultimate goal of outlining novel therapeutic strategies.
PB Springer Nature
YR 2024
FD 2024
LK https://hdl.handle.net/20.500.14352/97200
UL https://hdl.handle.net/20.500.14352/97200
LA eng
NO Ambrosini, G., Cordani, M., Zarrabi, A. et al. Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies. Cell Commun Signal 22, 36 (2024). https://doi.org/10.1186/s12964-023-01462-0
NO Ministry of Education, University and Research (Italy)
NO Ministerio de Ciencia, Innovación y Universidades (España)
NO Fondazione Umberto Veronesi
NO Principado de Asturias
NO Instituto de Salud Carlos III
NO European Commission
NO Comunidad de Madrid
DS Docta Complutense
RD 3 abr 2025